Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Up - What's Next?

Key Points

• Zealand Pharma A/S shares gapped up from a previous close of $50.14 to open at $53.50, with a trading volume of 126 shares.
• Wells Fargo, BNP Paribas, and Barclays have all upgraded Zealand Pharma A/S to a "strong-buy" rating, contributing to an average rating of "Strong Buy" from analysts.
• The company, based in Denmark, specializes in peptide-based medicines for gastrointestinal and metabolic diseases and has a market capitalization of $3.80 billion.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $50.14, but opened at $53.50. Zealand Pharma A/S shares last traded at $53.50, with a volume of 126 shares changing hands.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Barclays raised Zealand Pharma A/S to a "strong-buy" rating in a research report on Monday, July 7th. BNP Paribas raised shares of Zealand Pharma A/S to a "strong-buy" rating in a research note on Tuesday, July 1st. Finally, Wells Fargo & Company raised shares of Zealand Pharma A/S to a "strong-buy" rating in a research report on Thursday, July 24th. One research analyst has rated the stock with a buy rating and five have issued a strong buy rating to the company. Based on data from MarketBeat.com, Zealand Pharma A/S presently has an average rating of "Strong Buy".

Zealand Pharma A/S Price Performance

The company has a quick ratio of 25.07, a current ratio of 25.10 and a debt-to-equity ratio of 0.03. The stock's 50 day moving average price is $58.06 and its two-hundred day moving average price is $70.69. The stock has a market cap of $4.08 billion, a price-to-earnings ratio of 4.04 and a beta of 0.71.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported $16.06 earnings per share for the quarter, missing the consensus estimate of $16.72 by ($0.66). The company had revenue of $1.43 billion for the quarter, compared to analyst estimates of $9.18 billion. Zealand Pharma A/S had a return on equity of 82.30% and a net margin of 73.90%. Equities research analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.